Efficacy and safety of vismodegib: A new therapeutic agent in the treatment of basal cell carcinoma

Expert Opinion on Drug Safety

Volumn 13, Issue 8, 2014, Pages 1125-1132

  Lyons, Tomas G ^a   O'kane, Grainne M ^a   Kelly, Catherine M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Basal cell carcinoma; Hedgehog pathway; Vismodegib

Indexed keywords

SONIC HEDGEHOG PROTEIN; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ALOPECIA; AMENORRHEA; BASAL CELL CARCINOMA; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EARLY CANCER; FATIGUE; HUMAN; MUSCLE SPASM; NONHUMAN; PATHOGENESIS; REVIEW; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; DRUG APPROVAL; DRUG RESISTANCE; METASTASIS; PATHOLOGY; SKIN NEOPLASMS;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; NEOPLASM METASTASIS; PYRIDINES; SKIN NEOPLASMS;

EID: 84904512281     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.939952     Document Type: Review

References (32)

1. Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010;12(3):299-305
2. Grachtchouk M, Pero J, Yang SH, et al. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest 2011;121(5):1768-81
3. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283-7
4. National Cancer Institute. Skin cancer. 2014. Available from: Www.cancer.gov/ cancertopics/types/skin [Last accessed 13 May 2014]
5. Swanson EL, Amdur RJ, Mendenhall WM, et al. Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope 2009;119:2366-8
6. Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004;60(2):406
7. Macha MA, Batra SK, Ganti AK. Profile of Vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res 2013;5:197-203
8. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med 2004;6:530-9
9. Nüsslein-Volhard C, Wieschaus E. Mutation's affecting segment number and polarity in Drosophila. Nature 1980;287:795-801
10. Tang JY, So PL, Epstein EH. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol 2007;224:257-64
11. Theunissen JW, De Sauvage FJ. Paracrine hedgehog signalling in cancer. Cancer Res 2009;69:6007-10
12. Hui CC, Angers S. Gliproteins in development and disease. Annu Rev Cell Dev Biol 2011;27:513-17
13. Feldmann G, Dhara S, Fendrich V, et al. Blockade of Hedgehog signalling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96
14. De Zwaan SE, Haass NK. Genetics of basal cell carcinoma. Australas J Dermatol 2010;51(2):81-92
15. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-Acid glycoprotein binding. Clin Cancer Res 2011;17(8):2512-20
16. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17(8):2502-11
17. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17(17):5774-82
18. Sharma MR, Karrison TG, Kell B, et al. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res 2013;19(11):3059-67
19. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72
20. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9
21. Sekulic A, Schadendorf D, Solomon J, et al. Long-Term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. J Am Acad Dermatol 2014;70(5):AB137
22. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, Vismodegib. J Am Acad Dermatol 2014;70(1):60-9
23. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8
24. FDA news and events. Available from: Www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm289545.htm [Last accessed 13 May 2014]
25. Axelson M, Liu K, Jiang X, et al. US Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013;19:2289-93
26. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4
27. Rudin CM. Vismodegib. Clin Cancer Res 2012;18(12):3218-22
28. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71:435-44
29. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70
30. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hehgehog pathway activity and cancer growth. Cancer Cell 2010;17:388-99
31. Kim DJ, Spaunhurst K, Montoya J, et al. Open-label, exploratory Phase II trial of itraconazole for the treatment of basal cell carcinoma. J clin Oncol 2014;32(8):745-51
32. Lauth M, Bergstrom A, Shimokawa T, et al. GLI-mediated transcription and tumour cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007;104:8455-60